A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice

Wang, Dandan; Lu, Jin‐Jian; Yu, Jinfei; Hou, Hongjia; Leenhouts, Kees; Roosmalen, Maarten L. van; Gu, Tiejun; Jiang, Chunlai; Kong, Wei; Wu, Yongge

doi:10.1080/08820139.2018.1439505

Cited by 12 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They successfully showed induction of high levels of serum IgG and mucosal specific IgA against challenge in the murine model. Immunization with the PspA-BLP vaccine protected against lethal intranasal challenge with pneumococci from families 1 and 2 regardless of the serotype [147,149].…”

Section: Development Of Pneumococcal Nanovaccinesmentioning

confidence: 99%

“…Bacterium-like particles (BLPs) have the potential to serve as an immune stimulant in mucosal vaccine applications. Wang et al developed a novel PspA protein vaccine based on BLP delivery system that could provide broad protection against pneumococcal pneumonia in mice [147]. The shape and size of BLPs are similar to bacteria (between 0.5 to 5µm) and were made from the food-grade bacterium Lactococcus lactis through simple hot acid treatment.…”

Section: Development Of Pneumococcal Nanovaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection

et al. 2020

View full text Add to dashboard Cite

Streptococcus pneumoniae is a major pathogen causing pneumonia with over 2 million deaths annually, especially in young children and the elderly. To date, at least 98 different pneumococcal capsular serotypes have been identified. Currently, the vaccines for prevention of S. pneumoniae infections are the 23-valent pneumococcal polysaccharide-based vaccine (PPV23) and the pneumococcal conjugate vaccines (PCV10 and PCV13). These vaccines only cover some pneumococcal serotypes and are unable to protect against non-vaccine serotypes and unencapsulated S. pneumoniae. This has led to a rapid increase in antibiotic-resistant non-vaccine serotypes. Hence, there is an urgent need to develop new, effective, and affordable pneumococcal vaccines, which could cover a wide range of serotypes. This review discusses the new approaches to develop effective vaccines with broad serotype coverage as well as recent development of promising pneumococcal vaccines in clinical trials. New vaccine candidates are the inactivated whole-cell vaccine strain (Δpep27ΔcomD mutant) constructed by mutations of specific genes and several protein-based S. pneumoniae vaccines using conserved pneumococcal antigens, such as lipoprotein and surface-exposed protein (PspA). Among the vaccines in Phase 3 clinical trials are the pneumococcal conjugate vaccines, PCV-15 (V114) and 20vPnC. The inactivated whole-cell and several protein-based vaccines are either in Phase 1 or 2 trials. Furthermore, the recent progress of nanoparticles that play important roles as delivery systems and adjuvants to improve the performance, as well as the immunogenicity of the nanovaccines, are reviewed.

show abstract

Section: Development Of Pneumococcal Nanovaccinesmentioning

confidence: 99%

Section: Development Of Pneumococcal Nanovaccinesmentioning

confidence: 99%

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Though it should be noted that there have been previous concerns of host toxicity associated with bacterial-derived toxoid protein formulations when administered intranasally [133,134]. [147] Recombinant PspA (Nasal Gel) No adjuvant [53] Recombinant PspA (Intranasal Instillation) DOTAP/DC-chol liposome [148] Recombinant PspA (Intranasal Instillation) Chitosan [149] Recombinant PspA (Intranasal Instillation) Clostridium perfringens enterotoxin (C-CPE) [150] Recombinant PspA/BLP (Intranasal Instillation) No adjuvant [49] Recombinant PspA (nanoparticle absorbed) (Intranasal Instillation) (PGA-co-PDL) nanoparticles [151] Recombinant PLY (Intranasal Instillation) Aluminum hydroxide [152] Recombinant LytA (Intranasal Instillation) CpG oligodeoxynucleotides [153] Recombinant PspA/FlaB fusion (Intranasal Instillation) Recombinant FlaB [154] Live and/or Attenuated…”

Section: Intranasal Vaccine Delivery For Pneumococcal Diseasementioning

confidence: 99%

Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease

et al. 2021

View full text Add to dashboard Cite

This mini-review will cover recent trends in intranasal (IN) vaccine delivery as it relates to applications for respiratory tract diseases. The logic and rationale for IN vaccine delivery will be compared to methods and applications accompanying this particular administration route. In addition, we will focus extended discussion on the potential role of IN vaccination in the context of respiratory tract diseases, with a special emphasis on pneumococcal disease. Here, elements of this disease, including its prevalence and impact upon the elderly population, will be viewed from the standpoint of improving health outcomes through vaccine design and delivery technology and how IN administration can play a role in such efforts.

show abstract

“…Wang [11] has cited that Roozmalen et al developed an antigen delivery platform.. in his paper.so the number should be placed at the end of statement. developed an antigen delivery platform comprising bacterium-like particles (BLPs) for mucosal vaccines.…”

Section: Introductionmentioning

confidence: 99%

Humoral immunity provided by a novel infectious bronchitis vaccine supplemented by bacterium-like particles (BLPs)

Tohidi¹,

Ghaniei²,

Farzin³

et al. 2020

Turk J Vet Anim Sci

View full text Add to dashboard Cite

Infectious bronchitis (IB) is a notable disease of poultry flocks that results in economic loss. As a consequence of the presence of various IB virus (IBV) serotypes, control strategies, such as vaccination, should be replaced by provide broad protective immunity against the disease to date. Gram-positive enhancer matrix particles, or so-called bacterium like particles (BLPs), obtained from the bacterium Lactococcus lactis (L. lactis), have demonstrated an adjuvancy effect by providing demanding mucosal and humoral immune responses, as well as a protective cellular immunity whenever delivered admixed with a vaccine via intranasal or intraocular administration. In this study, for the first time, attempts were made to investigate the impact of an IBV vaccine supplemented by various doses of BLPs on induced levels of humoral immunity against IB. For this purpose, increasing doses of derived BLPs (0, 0.15, 0.3, and 0.6 mg dry weight per bird) were admixed with IBV live attenuated H120 serotype vaccine, and were delivered via ocular administration to 4 equal groups of 10 specific pathogen-free (SPF) chickens in 4 groups: control, BLP1, BLP2, and BLP3, respectively. In addition, 10 SPF chickens that were not immunized comprised the Unvaccinated group. Blood was collected from 5 members of each group weekly for 35 days. Levels of IgG antibodies in the sera were then assayed using ELISA. Weight gain and the feed conversion ratio of each group were also recorded weekly. Finally, 3 birds from each group were necropsied to evaluate probable lesions. The best results were obtained in the BLP1 group, with IBV vaccination at a low dose of admixed BLPs boosted immediate anti-IBV humoral responses; however, the results were not significantly different from those of the Control group, but were still feasible enough for application in the field. In conclusion, BLPs could be a desirable adjuvant for IBV vaccines to increase immunity in chickens.

show abstract

A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice

Abstract: Thus, targeted delivery of multiple bacterial antigens via BLPs may prevent pneumococcal disease by inducing both systemic and mucosal immune responses.

Cited by 12 publications

References 31 publications

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection

Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease

Humoral immunity provided by a novel infectious bronchitis vaccine supplemented by bacterium-like particles (BLPs)

Contact Info

Product

Resources

About